Eric Joseph Daniels - 01 Feb 2022 Form 4 Insider Report for KIORA PHARMACEUTICALS INC (KPRX)

Role
Chief Development Officer
Signature
/s/ Sarah Romano, Attorney-in-Fact*
Issuer symbol
KPRX
Transactions as of
01 Feb 2022
Net transactions value
$0
Form type
4
Filing time
03 Feb 2022, 18:03:48 UTC
Previous filing
10 Nov 2021
Next filing
25 Oct 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KPRX Stock Option (right to buy) Award $0 +25,000 $0.000000 25,000 01 Feb 2022 Common Stock 25,000 $0.7700 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.